Dogwood Therapeutics Announces Phase 2b Clinical Trial of Halneuron® for Chemotherapy-Induced Neuropathic Pain

Reuters

Oct 07

<a href="https://laohu8.com/S/DWTX">Dogwood Therapeutics</a> Announces Phase 2b Clinical Trial of Halneuron® for Chemotherapy-Induced Neuropathic Pain

Dogwood Therapeutics Inc. (Nasdaq:DWTX), a development-stage biotechnology company, has announced that its Chief Medical Officer, Dr. Michael Gendreau, will present an overview of the Halneuron® (tetrodotoxin) pain management research program at the upcoming 19th Annual Pain Therapeutics Summit on October 14, 2025. Halneuron® is currently being evaluated in a Phase 2b clinical trial (HALT-CINP) at 25 sites across the United States. The study aims to assess the safety and efficacy of low dose injectable Halneuron® in reducing chemotherapy induced neuropathic pain (CINP) in cancer patients. To date, more than 700 patients have participated in clinical studies with tetrodotoxin for various indications. Results from the current Phase 2b study have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1083674) on October 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573624950"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573624950\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573624950?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 20:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573624950","market":"fut","top_or_hot":-1,"title":"Dogwood Therapeutics Announces Phase 2b Clinical Trial of Halneuron® for Chemotherapy-Induced Neuropathic Pain","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DWTX\">Dogwood Therapeutics</a> Announces Phase 2b Clinical Trial of Halneuron® for Chemotherapy-Induced Neuropathic Pain\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Dogwood <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. (Nasdaq:DWTX), a development-stage biotechnology company, has announced that its Chief Medical Officer, Dr. Michael Gendreau, will present an overview of the Halneuron® (tetrodotoxin) pain management research program at the upcoming 19th Annual Pain Therapeutics <a href=\"https://laohu8.com/S/SMMT\">Summit</a> on October 14, 2025. Halneuron® is currently being evaluated in a Phase 2b clinical trial (HALT-CINP) at 25 sites across the United States. The study aims to assess the safety and efficacy of low dose injectable Halneuron® in reducing chemotherapy induced neuropathic pain (CINP) in cancer patients. To date, more than 700 patients have participated in clinical studies with tetrodotoxin for various indications. Results from the current Phase 2b study have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1083674) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dogwood Therapeutics Announces Phase 2b Clinical Trial of Halneuron® for Chemotherapy-Induced Neuropathic Pain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDogwood Therapeutics Announces Phase 2b Clinical Trial of Halneuron® for Chemotherapy-Induced Neuropathic Pain\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-07 20:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DWTX\">Dogwood Therapeutics</a> Announces Phase 2b Clinical Trial of Halneuron® for Chemotherapy-Induced Neuropathic Pain\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Dogwood <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. (Nasdaq:DWTX), a development-stage biotechnology company, has announced that its Chief Medical Officer, Dr. Michael Gendreau, will present an overview of the Halneuron® (tetrodotoxin) pain management research program at the upcoming 19th Annual Pain Therapeutics <a href=\"https://laohu8.com/S/SMMT\">Summit</a> on October 14, 2025. Halneuron® is currently being evaluated in a Phase 2b clinical trial (HALT-CINP) at 25 sites across the United States. The study aims to assess the safety and efficacy of low dose injectable Halneuron® in reducing chemotherapy induced neuropathic pain (CINP) in cancer patients. To date, more than 700 patients have participated in clinical studies with tetrodotoxin for various indications. Results from the current Phase 2b study have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1083674) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL3prpWM:1","article_id":"2573624950","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573624950","pubTimestamp":1759841123,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Dogwood Therapeutics Inc. , a development-stage biotechnology company, has announced that its Chief Medical Officer, Dr. Michael Gendreau, will present an overview of the Halneuron  pain management research program at the upcoming 19th Annual Pain Therapeutics Summit on October 14, 2025. Halneuron is currently being evaluated in a Phase 2b clinical trial  at 25 sites across the United States. The study aims to assess the safety and efficacy of low dose injectable Halneuron in reducing chemotherapy induced neuropathic pain  in cancer patients. To date, more than 700 patients have participated in clinical studies with tetrodotoxin for various indications. Results from the current Phase 2b study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4547":"WSB热门概念","BK4588":"碎股","BK4139":"生物科技","SAVA":"Cassava Sciences Inc","BK4007":"制药","DWTX":"DOGWOOD THERAPEUTICS INC"},"translate_title":"Dogwood Therapeutics宣布Halneuron的2b期临床试验®用于化疗引起的神经病理性疼痛","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DWTX":0.9,"SAVA":0.9},"content_text":"Dogwood Therapeutics Announces Phase 2b Clinical Trial of Halneuron® for Chemotherapy-Induced Neuropathic Pain\n    \n\n        Dogwood Therapeutics Inc. (Nasdaq:DWTX), a development-stage biotechnology company, has announced that its Chief Medical Officer, Dr. Michael Gendreau, will present an overview of the Halneuron® (tetrodotoxin) pain management research program at the upcoming 19th Annual Pain Therapeutics Summit on October 14, 2025. Halneuron® is currently being evaluated in a Phase 2b clinical trial (HALT-CINP) at 25 sites across the United States. The study aims to assess the safety and efficacy of low dose injectable Halneuron® in reducing chemotherapy induced neuropathic pain (CINP) in cancer patients. To date, more than 700 patients have participated in clinical studies with tetrodotoxin for various indications. Results from the current Phase 2b study have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1083674) on October 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}